Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Antiinflammatory strategies, not just B cell depletion, are required for optimal therapy for severe proliferative lupus nephritis: comment on the article by Rovin et al.

Kirou KA, Gkrouzman E, Chevalier JM, Seshan SV.

Arthritis Rheum. 2012 Oct;64(10):3486; author reply 3486. doi: 10.1002/art.34617. No abstract available.

2.

Response to 'Are steroids required for induction therapy and relapses in lupus nephritis?' by Abud-Mendoza et al.

Condon M.

Ann Rheum Dis. 2013 Dec;72(12):e30. doi: 10.1136/annrheumdis-2013-204331. Epub 2013 Sep 27. No abstract available.

PMID:
24078676
3.

Are steroids required for induction therapy and relapses in lupus nephritis?

Abud-Mendoza C, González-Amaro R.

Ann Rheum Dis. 2013 Dec;72(12):e29. doi: 10.1136/annrheumdis-2013-204321. Epub 2013 Aug 13. No abstract available.

PMID:
23942867
4.

Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts.

Jónsdóttir T, Gunnarsson I, Mourão AF, Lu TY, van Vollenhoven RF, Isenberg D.

Rheumatology (Oxford). 2010 Aug;49(8):1502-4. doi: 10.1093/rheumatology/keq055. Epub 2010 Apr 27.

PMID:
20427294
5.

Rituximab-treated membranous lupus nephritis: clinical outcome and effects on electron dense deposits.

Jónsdóttir T, Sundelin B, Welin Henriksson E, van Vollenhoven RF, Gunnarsson I.

Ann Rheum Dis. 2011 Jun;70(6):1172-3. doi: 10.1136/ard.2010.129288. Epub 2011 Mar 2. No abstract available.

PMID:
21367763
6.

Rituximab, a viable alternative for induction therapy of active lupus nephritis.

Zhou XJ, Zhao MH, Zhang H.

Rheumatology (Oxford). 2014 Sep;53(9):1537-8. doi: 10.1093/rheumatology/keu152. Epub 2014 Apr 12. No abstract available.

PMID:
24729446
7.

Lupus nephritis: a rituximab-based regimen might enable oral steroid avoidance in lupus nephritis.

Killock D.

Nat Rev Rheumatol. 2013 Aug;9(8):443. doi: 10.1038/nrrheum.2013.102. Epub 2013 Jun 25. No abstract available.

PMID:
23797310
8.

Rituximab in the treatment of refractory lupus nephritis with vasculitis.

Kadikoy H, Haque W, Ahmed S, Abdellatif A.

Saudi J Kidney Dis Transpl. 2012 Mar;23(2):334-7.

9.

The landscape after LUNAR: rituximab's crater-filled path.

Lightstone L.

Arthritis Rheum. 2012 Apr;64(4):962-5. doi: 10.1002/art.34362. Epub 2012 Jan 9. No abstract available.

10.

Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study.

Moroni G, Gallelli B, Sinico RA, Romano G, Sinigaglia L, Messa P.

Ann Rheum Dis. 2012 Oct;71(10):1751-2. doi: 10.1136/annrheumdis-2012-201442. Epub 2012 May 14. No abstract available.

PMID:
22586177
11.

Efficacy of low-dose versus high-dose cyclophosphamide in lupus nephritis: comment on the article by Houssiau et al.

Block JA.

Arthritis Rheum. 2003 May;48(5):1466; author reply 1466-7. No abstract available.

12.

Efficacy of rituximab in a patient with lupus nephritis despite low levels of CD19.

Bacconnier L, Combe B, Canaud B, Morel J.

Rheumatology (Oxford). 2010 Dec;49(12):2452-3. doi: 10.1093/rheumatology/keq186. Epub 2010 Jun 29. No abstract available.

PMID:
20591832
13.

Targeting B-cells in lupus nephritis: should cautious optimism remain?

Rovin BH.

Nephrol Dial Transplant. 2013 Jan;28(1):7-9. doi: 10.1093/ndt/gfs319. Epub 2012 Jul 26. No abstract available.

PMID:
22844105
14.

[Molecular targets and their regulation in systemic lupus erythematosus and lupus nephritis].

Takasaki Y.

Nihon Jinzo Gakkai Shi. 2012;54(5):598-602. Review. Japanese. No abstract available.

PMID:
22991839
15.
16.

[Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].

Petrović R, Stojanović R, Novicić-Sasić D, Dimitrijević J, Pavlović S, Stojković D, Palić-Obradović D, Stevanović G, Prodanović S.

Srp Arh Celok Lek. 2002 Aug;130 Suppl 3:19-25. Serbian.

PMID:
12583309
17.

Belimumab after rituximab as maintenance therapy in lupus nephritis.

Kraaij T, Huizinga TW, Rabelink TJ, Teng YK.

Rheumatology (Oxford). 2014 Nov;53(11):2122-4. doi: 10.1093/rheumatology/keu369. Epub 2014 Sep 8. No abstract available.

PMID:
25205827
18.

[The LUNAR study: rituximab for lupus nephritis?].

Specker C.

Z Rheumatol. 2013 Apr;72(3):300-2. doi: 10.1007/s00393-012-1111-8. German. No abstract available.

PMID:
23262655
19.

Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.

Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF.

Arthritis Rheum. 2007 Apr;56(4):1263-72.

20.

Epidemiology and management of refractory lupus nephritis.

Pons-Estel GJ, Serrano R, Plasín MA, Espinosa G, Cervera R.

Autoimmun Rev. 2011 Sep;10(11):655-63. doi: 10.1016/j.autrev.2011.04.032. Epub 2011 May 1. Review.

PMID:
21565286

Supplemental Content

Support Center